glecaprevir/pibrentasvir vs itraconazole
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of glecaprevir/pibrentasvir and itraconazole. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
moderate Known Drug Interaction
Elbasvir/grazoprevir Glecaprevir/pibrentasvir Tenofovir disoproxil fumarate Not recommended during and 2 weeks after itraconazole treatment.
Mavyret
Sporanox
Mavyret is a medicine used to treat hepatitis C (HCV) in adults and children 3 years and older. It contains two drugs, glecaprevir and pibrentasvir, that work together to stop the virus from multiplying.
Itraconazole capsules are an antifungal medicine. They treat fungal infections in your body.
Mavyret treats hepatitis C virus (HCV) genotypes 1, 2, 3, 4, 5, or 6. It can be used in people without cirrhosis or with compensated cirrhosis. Mavyret can also treat genotype 1 in people who have already been treated with certain other HCV medicines.
Itraconazole treats fungal infections like blastomycosis, histoplasmosis, and aspergillosis. It can help both people with healthy immune systems and those with weakened immune systems. It also treats onychomycosis, a fungal infection of the toenails or fingernails.
Mavyret contains glecaprevir and pibrentasvir. Glecaprevir blocks a protein called NS3/4A protease that the virus needs to multiply. Pibrentasvir blocks a protein called NS5A, also needed for the virus to multiply. By blocking these proteins, Mavyret stops the hepatitis C virus from spreading in your body.
Itraconazole stops fungi from growing. It does this by interfering with the production of a substance fungi need to build their cell membranes. This eventually kills the fungus and clears the infection.
- • Headache
- • Feeling tired
- • Nausea
- • Nausea
- • Rash
- • Headache
- Feeling tired 2,561
- Headache 2,203
- Nausea 1,125
- Itching 653
- Diarrhea 477
- Drug Interaction 1,118
- Pyrexia 568
- Dyspnoea 474
- Pneumonia 461
- Nausea 445
Mavyret can cause hepatitis B to become active again if you have had it in the past. This can cause serious liver problems, including liver failure and death. Your doctor will test you for hepatitis B before you start Mavyret. They will also monitor you during and after treatment.
Itraconazole can cause congestive heart failure. You should not take this medicine if you have heart problems. Itraconazole can also interact with many other medicines. Some of these interactions can be dangerous or even fatal. Check with your doctor about all the medicines you take.
It is not known if Mavyret will harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not known if Mavyret passes into breast milk. Talk to your doctor about the best way to feed your baby if you are taking Mavyret.
You should not take itraconazole if you are pregnant or plan to become pregnant. It can harm your unborn baby. Talk to your doctor about safe alternatives.
Also Compare, Nearby Drugs
Compare itraconazole with
How to Read This glecaprevir/pibrentasvir vs itraconazole Comparison
glecaprevir/pibrentasvir is classified in the NS3/4A/NS5A Inhibitor (HCV) drug class, while itraconazole sits within the Azole Antifungal class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, glecaprevir/pibrentasvir has 7,019 submissions while itraconazole has 3,066. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known moderate interaction flagged in FDA labeling, attributed to itraconazole blocks the body's ability to break down these hepatitis c medicines. this can cause the drugs to build up to high levels in your blood.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for glecaprevir/pibrentasvir or itraconazole.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.